Is alcohol required for effective pancreatic cyst ablation? The prospective randomized CHARM trial pilot study

Matthew T Moyer, Charles E Dye, Setareh Sharzehi, Brooke Ancrile, Abraham Mathew, Thomas J McGarrity, Niraj Gusani, Nelson Yee, Joyce Wong, John Levenick, Brandy Dougherty-Hamod, Bradley Mathers, Matthew T Moyer, Charles E Dye, Setareh Sharzehi, Brooke Ancrile, Abraham Mathew, Thomas J McGarrity, Niraj Gusani, Nelson Yee, Joyce Wong, John Levenick, Brandy Dougherty-Hamod, Bradley Mathers

Abstract

Background and study aims: In this study, we aim to determine the safety and feasibility of an alcohol-free approach to pancreatic cyst ablation using a chemotherapeutic ablation cocktail.

Patients and methods: In this prospective, randomized, double-blinded pilot study, 10 patients with known mucinous type pancreatic cysts underwent endoscopic ultrasound (EUS)-guided fine needle aspiration and then lavage with either 80 % ethanol or normal saline. Both groups were then treated with a cocktail of paclitaxel and gemcitabine. Primary outcomes were reduction in cyst volume and rates of complications.

Results: At 6 months, patients randomized to the alcohol arm had an 89 % average volume reduction, with a 91 % reduction noted in the alcohol-free arm. Complete ablation was achieved in 67 % of patients in the alcohol-free arm at both 6 and 12 months, whereas the alcohol group recorded complete ablation rates of 50 % and 75 % at 6 and 12 months, respectively. One patient in the alcohol arm developed acute pancreatitis (20 %) with no adverse events in the alcohol-free arm.

Conclusions: This study revealed similar ablation rates between the alcohol ablation group and the alcohol-free arm and demonstrates the safety and feasibility of an alcohol-free ablation protocol. This pilot study suggests that alcohol may not be required for effective cyst ablation.

Conflict of interest statement

Competing interests: Abraham Mathew: Consultant for Boston Scientific since 2013. Matthew T. Moyer: Consultant for Boston Scientific since 2012.

Figures

Fig. 1
Fig. 1
In use compatibility and stability testing of gemcitabine/paclitaxel, as measured by HPLC analysis. Gemcitabine (Gemzar, Eli Lilly, 38 mg/mL) and paclitaxel (Hospira, 6 mg/mL) were mixed 1:1 in a syringe and stored at room temperature for 24 hours. Analyte peak area was measured to indicate the amount of gemcitabine (a) and paclitaxel (b) in the original formulations compared to the 1:1 mixture.
Fig. 2 a
Fig. 2 a
MRI image showing a 76-year-old female with a 4.2-cm mucinous (premalignant) type pancreatic cyst (white arrow) prior to EUS-guided chemoablation. b CT image showing a 4-mm residual defect at 1 year (black arrow).
Fig. 3
Fig. 3
Volume of cysts post-treatment

References

    1. Ryan D P, Hong T S, Bardeesy N. Pancreatic adenocarcinoma. N Engl J Med. 2014;371:1039–1049.
    1. de Jong K, Nio C Y, Hermans J J. et al.High prevalence of pancreatic cysts detected by screening magnetic resonance imaging examinations. Clin Gastroenterol Hepatol. 2010;8:806–811.
    1. Kiely J M, Nakeeb A, Komorowski R A. et al.Cystic pancreatic neoplasms: enucleate or resect? J Gastrointest Surg. 2003;7:890–897.
    1. Allen P J, D’Angelica M, Gonen M. et al.A selective approach to the resection of cystic lesions of the pancreas: results from 539 consecutive patients. Ann Surg. 2006;244:572–582.
    1. Goh B K, Tan Y M, Cheow P C. et al.Cystic lesions of the pancreas: an appraisal of an aggressive resectional policy adopted at a single institution during 15 years. Am J Surg. 2006;192:148–154.
    1. Oh H C, Brugge W R. EUS-guided pancreatic cyst ablation: a critical review (with video) Gastrointest Endosc. 2013;77:526–533.
    1. DeWitt J, McGreevy K, Schmidt C M. et al.EUS-guided ethanol versus saline solution lavage for pancreatic cysts: a randomized, double-blind study. Gastrointest Endosc. 2009;70:710–723.
    1. Oh H C, Seo D W, Lee T Y. et al.New treatment for cystic tumors of the pancreas: EUS-guided ethanol lavage with paclitaxel injection. Gastrointest Endosc. 2008;67:636–642.
    1. DeWitt J M, Al-Haddad M, Sherman S. et al.Alterations in cyst fluid genetics following endoscopic ultrasound-guided pancreatic cyst ablation with ethanol and paclitaxel. Endoscopy. 2014;46:457–464.
    1. Gardner T. Best of ACG 2012. Gastroenterology & Endoscopy News December. 2012:20–21.
    1. Venook A P, Egorin M J, Rosner G L. et al.Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: Cancer and Leukemia Group B 9565. J Clin Oncol. 2000;18:2780–2787.
    1. Kiani A, Kohne C H, Franz T. et al.Pharmacokinetics of gemcitabine in a patient with end-stage renal disease: effective clearance of its main metabolite by standard hemodialysis treatment. Cancer Chemother Pharmacol. 2003;51:266–270.
    1. Von Hoff D D, Ervin T, Arena F P. et al.Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369:1691–1703.
    1. Tanaka M, Fernandez-del Castillo C, Adsay V. et al.International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. Pancreatology. 2012;12:183–197.
    1. Gan S I, Thompson C C, Lauwers G Y. et al.Ethanol lavage of pancreatic cystic lesions: initial pilot study. Gastrointest Endosc. 2005;61:746–752.
    1. Guidance for Clinical Investigators, Sponsors, and IRBs: Adverse Event Reporting to IRB’s-Improving Human Subject Protection. Jan, 2009.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren